Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

53.66 (USD) • At close January 15, 2025
Bedrijfsnaam Rhythm Pharmaceuticals, Inc.
Symbool RYTM
Munteenheid USD
Prijs 53.66
Beurswaarde 3,297,787,986
Dividendpercentage 0%
52-weken bereik 35.17 - 68.58
Industrie Biotechnology
Sector Healthcare
CEO Dr. David P. Meeker M.D.
Website https://www.rhythmtx.com

An error occurred while fetching data.

Over Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency

Vergelijkbare Aandelen

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.359 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Profound Medical Corp. logo

Profound Medical Corp.

PROF

7.38 USD

Talkspace, Inc. logo

Talkspace, Inc.

TALK

2.94 USD

Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc.

ALDX

5.025 USD

Mainz Biomed B.V. logo

Mainz Biomed B.V.

MYNZ

5 USD

CymaBay Therapeutics, Inc. logo

CymaBay Therapeutics, Inc.

CBAY

32.48 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)